From Wiki Journal Club
Jump to: navigation, search
Kantarjian H, et al. "Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia". The New England Journal of Medicine. 2010. 362(24):2260-70.
PubMedFull textPDF

Clinical Question

Among patients with chronic-phase CML, does front-line therapy with dasatinib induce more rapid complete cytogenetic responses compared to the standard of care imatinib?

Bottom Line

Among patients with chronic-phase CML, front-line dasatinib induces more complete cytogenetic responses at 12 months compared to imatinib.

Major Points

IRIS (2003) was the first randomized trial to demonstrate the benefit of the tyrosine kinase inhibitor (TKI) imatinib over conventional therapy for patients with chronic-phase chronic myeloid leukemia (CML). Subsequently, several second-generation TKIs have been developed including dasatinib, nilotinib, and bosutinib, which may induce a more rapid response compared to imatinib.

Published in 2010, the Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) study...

Follow-up data.[1] Editorial.[2] Comments.[3]



  • N=
    • (n=)
    • (n=)
  • Setting:
  • Enrollment:
  • Mean follow-up:
  • Analysis:
  • Primary outcome:


Inclusion Criteria

Exclusion Criteria

Baseline Characteristics



Primary Outcome

 % vs. % (## HR; 95% CI ##-##; P=##; NNT/NNH=##)

Secondary Outcomes

Subgroup Analysis

Adverse Events

 % vs. % (## HR; 95% CI ##-##; P=##; NNH=##)



Further Reading